Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC)

A. Y. Bedikian, R. Staab, Robert B Livingston, M. Valdivieso, M. A. Burgess, G. P. Bodey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thirty-one adult patients with adenocarcinoma of the lung were treated with FCC chemotherapy consisting of 5-fluorouracil (5-FU), cyclophosphamide, and CCNU every 4 weeks. Thirteen patients received 5-FU orally (POF) at the dose of 400 μg/m 2/day in 4 divided daily doses for 5 days, whereas 18 patients recived 5-FU at the dose of 800 mg/m 2/day for 5 days as a continuous intravenous infusion (CIF). All patients received cyclophosphamide and CCNU orally at doses of 200 mg/m 2/day for 4 days and 40 mg/m 2/day for two days, respectively. The overall response was 22%. Response was greater in patients treated with FCC-CIF (4/14 vs. 1/9; p = 0.6), in patients with limited disease (4/13 vs. 1/10; p = 0.5), and in patients with good performance status, (14/16 vs. 1/7). The overall median survival duration was 9 months. The patients who achieved tumor-reggression survived significantly longer than patients who had disease stabilization (median, 21 vs. 9 months; p = 0.01), and the latter survived significantly longer than patients who had progressive disease (median, 9 vs. 2.5 months; p = 0.003). There was no significant difference of disease and performance status did not influence the survival of patients. However, the FCC-CIF-treated group contained a greater number of patients with extensive disease and poor performance status. Further investigations are indicated to evaluate the efficacy of 5-fluorouracil administered by continuous intravenous infusion in combination with cyclophosphamide and CCNU in bronchogenic carcinoma.

Original languageEnglish (US)
Pages (from-to)858-863
Number of pages6
JournalCancer
Volume44
Issue number3
DOIs
StatePublished - 1979
Externally publishedYes

Fingerprint

Lomustine
Fluorouracil
Cyclophosphamide
Drug Therapy
Intravenous Infusions
Adenocarcinoma of lung
Survival
Bronchogenic Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC). / Bedikian, A. Y.; Staab, R.; Livingston, Robert B; Valdivieso, M.; Burgess, M. A.; Bodey, G. P.

In: Cancer, Vol. 44, No. 3, 1979, p. 858-863.

Research output: Contribution to journalArticle

Bedikian, A. Y. ; Staab, R. ; Livingston, Robert B ; Valdivieso, M. ; Burgess, M. A. ; Bodey, G. P. / Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC). In: Cancer. 1979 ; Vol. 44, No. 3. pp. 858-863.
@article{a505fd703faa4956bb9f1e120f5503c9,
title = "Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC)",
abstract = "Thirty-one adult patients with adenocarcinoma of the lung were treated with FCC chemotherapy consisting of 5-fluorouracil (5-FU), cyclophosphamide, and CCNU every 4 weeks. Thirteen patients received 5-FU orally (POF) at the dose of 400 μg/m 2/day in 4 divided daily doses for 5 days, whereas 18 patients recived 5-FU at the dose of 800 mg/m 2/day for 5 days as a continuous intravenous infusion (CIF). All patients received cyclophosphamide and CCNU orally at doses of 200 mg/m 2/day for 4 days and 40 mg/m 2/day for two days, respectively. The overall response was 22{\%}. Response was greater in patients treated with FCC-CIF (4/14 vs. 1/9; p = 0.6), in patients with limited disease (4/13 vs. 1/10; p = 0.5), and in patients with good performance status, (14/16 vs. 1/7). The overall median survival duration was 9 months. The patients who achieved tumor-reggression survived significantly longer than patients who had disease stabilization (median, 21 vs. 9 months; p = 0.01), and the latter survived significantly longer than patients who had progressive disease (median, 9 vs. 2.5 months; p = 0.003). There was no significant difference of disease and performance status did not influence the survival of patients. However, the FCC-CIF-treated group contained a greater number of patients with extensive disease and poor performance status. Further investigations are indicated to evaluate the efficacy of 5-fluorouracil administered by continuous intravenous infusion in combination with cyclophosphamide and CCNU in bronchogenic carcinoma.",
author = "Bedikian, {A. Y.} and R. Staab and Livingston, {Robert B} and M. Valdivieso and Burgess, {M. A.} and Bodey, {G. P.}",
year = "1979",
doi = "10.1002/1097-0142(197909)44:3<858::AID-CNCR2820440310>3.0.CO;2-P",
language = "English (US)",
volume = "44",
pages = "858--863",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC)

AU - Bedikian, A. Y.

AU - Staab, R.

AU - Livingston, Robert B

AU - Valdivieso, M.

AU - Burgess, M. A.

AU - Bodey, G. P.

PY - 1979

Y1 - 1979

N2 - Thirty-one adult patients with adenocarcinoma of the lung were treated with FCC chemotherapy consisting of 5-fluorouracil (5-FU), cyclophosphamide, and CCNU every 4 weeks. Thirteen patients received 5-FU orally (POF) at the dose of 400 μg/m 2/day in 4 divided daily doses for 5 days, whereas 18 patients recived 5-FU at the dose of 800 mg/m 2/day for 5 days as a continuous intravenous infusion (CIF). All patients received cyclophosphamide and CCNU orally at doses of 200 mg/m 2/day for 4 days and 40 mg/m 2/day for two days, respectively. The overall response was 22%. Response was greater in patients treated with FCC-CIF (4/14 vs. 1/9; p = 0.6), in patients with limited disease (4/13 vs. 1/10; p = 0.5), and in patients with good performance status, (14/16 vs. 1/7). The overall median survival duration was 9 months. The patients who achieved tumor-reggression survived significantly longer than patients who had disease stabilization (median, 21 vs. 9 months; p = 0.01), and the latter survived significantly longer than patients who had progressive disease (median, 9 vs. 2.5 months; p = 0.003). There was no significant difference of disease and performance status did not influence the survival of patients. However, the FCC-CIF-treated group contained a greater number of patients with extensive disease and poor performance status. Further investigations are indicated to evaluate the efficacy of 5-fluorouracil administered by continuous intravenous infusion in combination with cyclophosphamide and CCNU in bronchogenic carcinoma.

AB - Thirty-one adult patients with adenocarcinoma of the lung were treated with FCC chemotherapy consisting of 5-fluorouracil (5-FU), cyclophosphamide, and CCNU every 4 weeks. Thirteen patients received 5-FU orally (POF) at the dose of 400 μg/m 2/day in 4 divided daily doses for 5 days, whereas 18 patients recived 5-FU at the dose of 800 mg/m 2/day for 5 days as a continuous intravenous infusion (CIF). All patients received cyclophosphamide and CCNU orally at doses of 200 mg/m 2/day for 4 days and 40 mg/m 2/day for two days, respectively. The overall response was 22%. Response was greater in patients treated with FCC-CIF (4/14 vs. 1/9; p = 0.6), in patients with limited disease (4/13 vs. 1/10; p = 0.5), and in patients with good performance status, (14/16 vs. 1/7). The overall median survival duration was 9 months. The patients who achieved tumor-reggression survived significantly longer than patients who had disease stabilization (median, 21 vs. 9 months; p = 0.01), and the latter survived significantly longer than patients who had progressive disease (median, 9 vs. 2.5 months; p = 0.003). There was no significant difference of disease and performance status did not influence the survival of patients. However, the FCC-CIF-treated group contained a greater number of patients with extensive disease and poor performance status. Further investigations are indicated to evaluate the efficacy of 5-fluorouracil administered by continuous intravenous infusion in combination with cyclophosphamide and CCNU in bronchogenic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0018712776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018712776&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197909)44:3<858::AID-CNCR2820440310>3.0.CO;2-P

DO - 10.1002/1097-0142(197909)44:3<858::AID-CNCR2820440310>3.0.CO;2-P

M3 - Article

C2 - 476597

AN - SCOPUS:0018712776

VL - 44

SP - 858

EP - 863

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -